Detailed Information on Publication Record
2018
Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
VESELKA, Josef, Lothar FABER, Morten Kvistholm JENSEN, Robert COOPER, Jaroslav JANUSKA et. al.Basic information
Original name
Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
Authors
VESELKA, Josef (203 Czech Republic, guarantor), Lothar FABER (276 Germany), Morten Kvistholm JENSEN (208 Denmark), Robert COOPER (826 United Kingdom of Great Britain and Northern Ireland), Jaroslav JANUSKA (203 Czech Republic), Jan KREJČÍ (203 Czech Republic, belonging to the institution), Thomas BARTEL (784 United Arab Emirates), Maciej DABROWSKI (616 Poland), Peter Riis HANSEN (208 Denmark), Vibeke Marie ALMAAS (578 Norway), Hubert SEGGEWISS (276 Germany), Dieter HORSTKOTTE (276 Germany), Radka ADLOVA (203 Czech Republic), Henning BUNDGAARD (208 Denmark), Jurrien ten BERG (528 Netherlands) and Max LIEBREGTS (528 Netherlands)
Edition
Canadian Journal of Cardiology, New York, Elsevier Science Ltd. 2018, 0828-282X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 5.592
RIV identification code
RIV/00216224:14110/18:00105231
Organization unit
Faculty of Medicine
UT WoS
000418674300007
Keywords in English
hypertrophic cardiomyopathy
Tags
International impact, Reviewed
Změněno: 9/2/2019 22:30, Soňa Böhmová
Abstract
V originále
Background: The current American College of Cardiology Foundation/American Heart Association guidelines on hypertrophic cardiomyopathy state that institutional experience is a key determinant of successful outcomes and lower complication rates of alcohol septal ablation (ASA). The aim of this study was to evaluate the safety and efficacy of ASA according to institutional experience with the procedure. Methods: We retrospectively evaluated 1310 patients with symptomatic obstructive hypertrophic cardiomyopathy who underwent ASA and were divided into 2 groups. The first-50 group consisted of the first consecutive 50 patients treated at each centre, and the over-50 group consisted of patients treated thereafter (patients 51 and above). Results: In the 30-day follow-up, there was a significant difference in the occurrence of major cardiovascular adverse events (21% in the first-50 group vs 12% in the over-50 group; P < 0.01), which was driven by the occurrence of cardiovascular deaths (2.1% vs 0.4%; P = 0.01) and implanted pacemakers (15% vs 9%; P < 0.01). In the long-term follow-up (5.5 +/- 4.1 years), the first-50 group was associated with a significantly higher occurrence of major adverse events (P < 0.01) and higher cardiovascular mortality (P < 0.01). Also, patients in the first-50 group were more likely to self-report dyspnea of New York Heart Association class III/IV (16% vs 10%), to have a left ventricular outflow gradient > 30 mm Hg (16% vs 10%) at the last clinical check-up (P < 0.01 for both), and a probability of repeated septal reduction therapy (P = 0.03). Conclusions: An institutional experience of > 50 ASA procedures was associated with a lower occurrence of ASA complications, better cardiovascular survival, better hemodynamic and clinical effect, and less need for repeated septal reduction therapy.